Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1
Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
The five biotech ETFs have very different portfolios with markedly different performance.